Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
INTERVENTIONAL RADIOLOGY SERVICESDepartment of Veterans Affairs$1.4M obligationsEnds Mar 31, 2027
PET/CT RADIOPHARMACEUTICALSDepartment of Veterans Affairs$377.9K obligationsEnds Sep 30, 2027
RADIOPHARMACEUTICALS FOR MUSDepartment of Veterans Affairs$444.5K obligationsEnds Dec 31, 2026
RADIOPHARMACEUTICALS EO 14398Department of Veterans Affairs$444.4K obligationsEnds Sep 30, 2027
TRIPLE NEGATIVE BREAST CANCER VACCINESDepartment of Health and Human Services$1.1M obligationsEnds Sep 13, 2028
TO PROVIDE ACCREDITED CONTINUOUS EDUCATION DENTAL TRAINING SERVICES AND VENUEDepartment of Health and Human Services$13.8K obligationsEnds Aug 24, 2027
SEQUENCING SERVICES (RESEARCH - ACADEMIC AFFILIATE)Department of Veterans Affairs$39.5K obligationsEnds Jan 31, 2027
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: COLORECTAL CANCER (CRC) PREVENTION BY…Department of Health and Human Services$1.1M obligationsEnds Sep 10, 2027
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY…Department of Health and Human Services$982.3K obligationsEnds Aug 7, 2027
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCER IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE…Department of Health and Human Services$760.6K obligationsEnds Jun 16, 2026
PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMADepartment of Health and Human Services$1.0M obligationsEnds Sep 14, 2026
BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: FURTHER DEVELOPMENT OF…Department of Health and Human Services$1.2M obligationsEnds Mar 24, 2028
STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001Department of Health and Human Services$14.4M obligationsEnds Feb 14, 2027
STRONG HEART STUDY (SHS)- FIELD CENTER (FC)- TASK ORDER 001Department of Health and Human Services$5.3M obligationsEnds Feb 14, 2027
ASA RESEARCH FELLOWSHIPDepartment of Commerce$246.7K obligationsEnds Nov 30, 2026
OK, UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER SPR 1301319610Department of Defense$40.5K obligationsEnds Jun 30, 2026
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER SPR 1301336995Department of Defense$70.6K obligationsEnds Jun 30, 2026
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCERDepartment of Health and Human Services$1.1M obligationsEnds Nov 15, 2025
TUITION AND FEES OK, UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTERDepartment of Defense$20.0K obligationsEnds Jan 13, 2026
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.Department of Health and Human Services$910.0K obligationsEnds Nov 1, 2026
TUITION AND FEESDepartment of Defense$77.8K obligationsEnds Dec 31, 2025
STRONG HEART STUDY (SHS)- UNIVERSITY OF OKLAHOMA-FIELD CENTER (FC), TASK AREA B.3, YEAR 3Department of Health and Human Services$333.4K obligationsEnds Oct 31, 2026
OK, UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER TUITION AND FEES FOR FALL TERM AUG - DEC 2025Department of Defense$20.6K obligationsEnds Dec 31, 2025
STRONG HEART STUDY (SHS) - UNIVERSITY OF OKLAHOMA, FIELD CENTER (FC), TASK AREA C: DATA BOOKDepartment of Health and Human Services$469.0K obligationsEnds Feb 14, 2027
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDEDepartment of Health and Human Services$1.4M obligationsEnds Feb 4, 2027